ATE218135T1 - Zyklischaminosäure als pharmazeutische mittel - Google Patents

Zyklischaminosäure als pharmazeutische mittel

Info

Publication number
ATE218135T1
ATE218135T1 AT97901385T AT97901385T ATE218135T1 AT E218135 T1 ATE218135 T1 AT E218135T1 AT 97901385 T AT97901385 T AT 97901385T AT 97901385 T AT97901385 T AT 97901385T AT E218135 T1 ATE218135 T1 AT E218135T1
Authority
AT
Austria
Prior art keywords
pct
cyclic amino
amino acid
date
pharmaceutical agents
Prior art date
Application number
AT97901385T
Other languages
English (en)
Inventor
David C Horwell
Justin S Bryans
Clare O Kneen
Giles S Ratcliffe
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE218135T1 publication Critical patent/ATE218135T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
AT97901385T 1996-02-07 1997-01-02 Zyklischaminosäure als pharmazeutische mittel ATE218135T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1127896P 1996-02-07 1996-02-07
PCT/US1997/000255 WO1997029101A1 (en) 1996-02-07 1997-01-02 Novel cyclic amino acids as pharmaceutical agents

Publications (1)

Publication Number Publication Date
ATE218135T1 true ATE218135T1 (de) 2002-06-15

Family

ID=21749660

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97901385T ATE218135T1 (de) 1996-02-07 1997-01-02 Zyklischaminosäure als pharmazeutische mittel

Country Status (22)

Country Link
US (1) US5929088A (de)
EP (1) EP0888325B1 (de)
JP (1) JP2000511877A (de)
KR (1) KR19990082349A (de)
AT (1) ATE218135T1 (de)
AU (1) AU720628B2 (de)
BR (1) BR9707366A (de)
CA (1) CA2244708A1 (de)
CZ (1) CZ296052B6 (de)
DE (1) DE69712877T2 (de)
DK (1) DK0888325T3 (de)
EA (1) EA001534B1 (de)
ES (1) ES2176668T3 (de)
HU (1) HUP9901074A3 (de)
IL (1) IL125562A (de)
NO (1) NO983612L (de)
NZ (1) NZ326669A (de)
PL (1) PL328432A1 (de)
PT (1) PT888325E (de)
SK (1) SK282665B6 (de)
WO (1) WO1997029101A1 (de)
ZA (1) ZA97991B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0934061T1 (en) 1996-07-24 2003-10-31 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
PT1015415E (pt) 1997-09-18 2003-09-30 Warner Lambert Co Novos processos estereosselectivos para a preparacao de analogos de gabapentina
DE19751062A1 (de) * 1997-11-18 1999-07-08 Univ Ludwigs Albert An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
US6984659B2 (en) 1997-11-18 2006-01-10 Klinikum Der Albert-Ludwigs Universitaet 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
US6545022B1 (en) * 1997-12-16 2003-04-08 Pfizer Inc. 4(3)substituted-4(3)-aminomethyl-(thio)pyran or piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
EP1267896A1 (de) * 2000-03-28 2003-01-02 Robert J. Delorenzo Hemmung eines neuen calcium-strom, der sich bildet in neuronen während verletzungen darin, verhütet neuronalen zelltod
EP1361847A2 (de) 2000-10-06 2003-11-19 Xenoport, Inc. Gallensäurekonjugate zur bereitstellung anhaltender systemischer arneimittelkonzentrationen
US6992076B2 (en) 2000-10-06 2006-01-31 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
HUP0400183A2 (hu) 2001-06-11 2004-07-28 Xenoport Inc. Gaba-analóg prodrugok csökkentett toxicitású orális dózisformái
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2002100344A2 (en) 2001-06-11 2002-12-19 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
AU2003222033A1 (en) 2002-03-20 2003-10-08 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
WO2003099338A2 (en) 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US20040092498A1 (en) * 2002-08-16 2004-05-13 David Blakemore Substituted glycine derivatives for use as medicaments
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
RU2331438C2 (ru) 2002-12-13 2008-08-20 Уорнер-Ламберт Компани Ллс Альфа-2-дельта лиганд для лечения симптомов нижних мочевыводящих путей
JP2007505149A (ja) 2003-09-11 2007-03-08 ゼノポート，インコーポレイティド ギャバ類似体のプロドラッグを用いる尿失禁の治療および／あるいは予防
EP1663398B1 (de) 2003-09-12 2009-11-25 Pfizer Limited Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
NZ545989A (en) 2003-09-17 2009-10-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
MXPA06004088A (es) 2003-10-14 2006-06-27 Xenoport Inc Forma cristalina de un analogo del acido gamma-aminobutirico.
DK1691811T3 (da) 2003-12-11 2014-10-20 Sunovion Pharmaceuticals Inc Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
RU2440112C2 (ru) 2004-11-04 2012-01-20 Ксенопорт, Инк. Пероральная дозированная форма габапентина замедленного высвобождения
CN101600458A (zh) 2006-12-22 2009-12-09 瑞蔻达蒂爱尔兰有限公司 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
CA2697254A1 (en) * 2007-08-23 2009-02-26 Novartis Ag Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors
JP5563483B2 (ja) 2008-01-25 2014-07-30 ゼノポート，インコーポレイティド アシロキシアルキルカルバメートプロドラッグの合成に使用されるアシロキシアルキルチオカーボネートの鏡像異性的な分解
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
US7872046B2 (en) 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
BRPI0919811B1 (pt) 2008-10-08 2022-04-19 Xgene Pharmaceutical Inc Conjugados de gaba e métodos de uso dos mesmos
WO2010084797A1 (ja) * 2009-01-21 2010-07-29 第一三共株式会社 含ヘテロ原子化合物
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
US10130715B2 (en) 2013-01-28 2018-11-20 Hector L. Lopez Methods of improving tolerability, pharmacodynamics, and efficacy of β-alanine and use therefor
EP4227293A3 (de) 2018-05-14 2023-10-04 Xgene Pharmaceutical Inc Kristalline formen von 1-(acyloxy)-alkylcarbamat-wirkstoffkonjugaten von naproxen und pregabalin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
KR970010173B1 (ko) * 1991-07-09 1997-06-21 닛뽕소다 가부시끼가이샤 함헤테로 시클로헥산디온 유도체, 그의 제조방법 및 제초제
US5514801A (en) * 1992-12-29 1996-05-07 Monsanto Company Cyclic sulfone containing retroviral protease inhibitors
GB9314758D0 (en) * 1993-07-16 1993-08-25 Wyeth John & Brother Ltd Heterocyclic derivatives
US5527194A (en) * 1994-02-02 1996-06-18 Brunswick Corporation Thrust sensor for marine drives
US5491152A (en) * 1994-03-23 1996-02-13 The Du Pont Merck Pharmaceutical Company Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis
US5760006A (en) * 1997-06-23 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating psoriasis

Also Published As

Publication number Publication date
KR19990082349A (ko) 1999-11-25
EP0888325A1 (de) 1999-01-07
DK0888325T3 (da) 2002-09-16
CZ296052B6 (cs) 2005-12-14
BR9707366A (pt) 1999-07-20
AU720628B2 (en) 2000-06-08
HUP9901074A2 (hu) 2001-04-28
IL125562A (en) 2001-08-08
EA001534B1 (ru) 2001-04-23
CZ245298A3 (cs) 1998-11-11
NZ326669A (en) 2001-05-25
IL125562A0 (en) 1999-03-12
DE69712877D1 (de) 2002-07-04
PL328432A1 (en) 1999-02-01
SK282665B6 (sk) 2002-11-06
DE69712877T2 (de) 2002-11-14
HUP9901074A3 (en) 2001-08-28
EA199800682A1 (ru) 1999-02-25
PT888325E (pt) 2002-10-31
ES2176668T3 (es) 2002-12-01
SK106798A3 (en) 1999-07-12
CA2244708A1 (en) 1997-08-14
JP2000511877A (ja) 2000-09-12
EP0888325B1 (de) 2002-05-29
US5929088A (en) 1999-07-27
ZA97991B (en) 1997-08-15
NO983612D0 (no) 1998-08-06
AU1529597A (en) 1997-08-28
WO1997029101A1 (en) 1997-08-14
NO983612L (no) 1998-10-06

Similar Documents

Publication Publication Date Title
ATE218135T1 (de) Zyklischaminosäure als pharmazeutische mittel
ATE207878T1 (de) Zyklische aminosäure als pharmazeutische wirkstoffe
ATE210629T1 (de) Verbrückte zyklische aminosäuren als pharmazeutische mittel
DE69737719D1 (de) Substituierte gamma-aminobuttersäurederivate als arzneimittel
DE60000833T2 (de) Amino-heterocyclen zur verwendung als pharmazeutische mittel
CA2245647A1 (en) Novel bridged cyclic amino acids as pharmaceutical agents

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee